Analyst Ratings For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Today, Morgan Stanley lowered its price target on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to $99.00 per share.

There are 14 Buy Ratings, 3 Hold Ratings, 2 Sell Ratings, 1 Strong Buy Ratings on the stock.

The current consensus rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is Buy with a consensus target price of $142.95 per share, a potential 54.88% upside.

Some recent analyst ratings include

• 8/3/2018-Chardan Capital Reiterated Rating of Buy.
• 8/3/2018-BMO Capital Markets Reiterated Rating of Buy.
• 8/2/2018-Cowen Reiterated Rating of Buy.
• 7/23/2018-Piper Jaffray Companies Reiterated Rating of Overweight.
• 4/2/2018-B. Riley Reiterated Rating of Buy.

Recent Insider Trading Activity For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has insider ownership of 4.30% and institutional ownership of 90.72%.

• On 7/25/2018 John Maraganore, CEO, sold 50,000 with an average share price of $105.39 per share and the total transaction amounting to $5,269,500.00.
• On 6/20/2018 Laurie Keating, SVP, sold 1,563 with an average share price of $105.04 per share and the total transaction amounting to $164,177.52.
• On 3/26/2018 Yvonne Greenstreet, COO, sold 7,221 with an average share price of $136.54 per share and the total transaction amounting to $985,955.34.
• On 3/20/2018 Laurie Keating, SVP, sold 1,562 with an average share price of $149.83 per share and the total transaction amounting to $234,034.46.
• On 3/14/2018 Akshay Vaishnaw, Insider, sold 88,554 with an average share price of $143.10 per share and the total transaction amounting to $12,672,077.40.
• On 3/14/2018 Barry E Greene, President, sold 38,460 with an average share price of $143.10 per share and the total transaction amounting to $5,503,626.00.
• On 3/13/2018 Laurie Keating, SVP, sold 20,000 with an average share price of $145.00 per share and the total transaction amounting to $2,900,000.00.

About Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia. Its clinical programs also include ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR, which is in the Phase I clinical trial for the treatment of various forms of ATTR amyloidosis; Lumasiran (ALN-GO1) that is in Phase I/II clinical trial for the treatment of primary hyperoxaluria type 1; and Cemdisiran (ALN-CC5), which is in the Phase II clinical trial for the treatment of complement-mediated diseases. The company has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Recent Trading Activity for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Shares of Alnylam Pharmaceuticals, Inc. closed the previous trading session at 92.08 −3.14 3.30% with 96.32 shares trading hands.